JNJ · News · 20260913N

RYBR立VANT Head And Neck Expansion

JOHNSON & JOHNSON · 2026-09-13 · Importance 34 · Surprise 42

Johnson & Johnson reported final overall-survival results from the Phase 3 PAPILLON study of first-line intravenous RYBREVANT plus carboplatin-pemetrexed in advanced NSCLC with EGFR exon 20 insertion mutations. The combination delivered the longest reported median overall survival for this patient population versus chemotherapy alone, according to the company’s September 13, 2026 announcement. RYBREVANT’s dual targeting of EGFR and MET supports its oncology pipeline and expansion in a population with a historical five-year survival rate of 8%.